市场调查报告书
商品编码
1561454
2024-2032 年按产品、应用、最终用户和地区分類的 3D 细胞培养市场报告3D Cell Culture Market Report by Product, Application, End User, and Region 2024-2032 |
2023年,全球3D细胞培养市场规模达23.232IMARC Group美元。对用于诊断癌症的3D 组织工程模型的需求不断增长,对气道和气液界面类器官的需求不断增长,以及需要体内模型系统的研究中的利用率不断提高,这些都是推动市场发展的一些关键因素。
3D 细胞培养是一种培养环境,使细胞能够在三个维度上生长并与周围的细胞外框架相互作用。它与传统的 2D 细胞培养形成鲜明对比,传统的 2D 细胞培养中细胞在平板上的平坦单层中生长。它可以在支撑支架(例如水凝胶和惰性基质)中培养,以允许在各个方向上生长。它依赖于无支架方法,例如低黏附板、微图案表面和悬滴,使细胞能够自组装成簇或球体。它是在微晶片的室内进行的,微晶片允许液体流动,在整个细胞中运输和分配营养物质或其他化学物质。与二维细胞培养相比,它更准确地代表细胞驻留在组织中的实际微环境。由于 3D 培养的额外维度更能反映体内细胞反应,因此全球对 3D 细胞培养的需求正在上升。
目前,在需要体内模型系统的研究中越来越多地使用3D细胞培养,因为3D培养可以密切模仿器官的典型形态和微结构,这是支持市场成长的关键因素之一。除此之外,世界各地也越来越多地使用 3D 组织工程模型来诊断癌症和其他临床疾病。再加上对 3D 细胞培养分析外国药物对身体组织和器官影响的需求不断增长,提供了良好的市场前景。此外,与 2D 技术相比,3D 细胞培养是一种简单且廉价的体外肿瘤宿主环境,因此对 3D 细胞培养的需求不断增长,正在推动市场的成长。此外,越来越多地使用 3D 模型进行呼吸系统疾病研究,为行业投资者提供了利润丰厚的成长机会。除此之外,对气道和气液界面类器官的需求不断增加,以开发和发现抗病毒药物以及作为实验病毒学平台和研究免疫反应。再加上新产品的推出以及 3D 协定在生物研究中的广泛应用,正在加强市场的成长。
The global 3D cell culture market size reached US$ 2,323.2 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 7,418.7 Million by 2032, exhibiting a growth rate (CAGR) of 13.4% during 2024-2032. The growing demand for 3D tissue-engineered models to diagnose cancer, rising need for airway and air-liquid interface organoids, and increasing utilization in studies that require in vivo model systems represent some of the key factors driving the market.
3D cell culture is a culture environment that enables cells to grow and interact with surrounding extracellular frameworks in three dimensions. It is a contrast to traditional 2D cell cultures wherein cells are grown in a flat monolayer on a plate. It can be cultured within supporting scaffolds, such as hydrogels and inert matrices, to allow growth in all directions. It relies on scaffold-free methods, such as low-adhesion plates, micropatterned surfaces, and hanging drops, for allowing cells to self-assemble into clusters or spheroids. It is performed within the chambers of a microchip that allows the flow of liquid to transport and distribute nutrients or other chemicals throughout the cells. It represents more accurately the actual microenvironment wherein cells reside in tissues compared to 2D cell culture. As it is more reflective of in vivo cellular responses due to the additional dimensionality of 3D cultures, the demand for 3D cell culture is rising across the globe.
At present, the increasing utilization of 3D cell culture in studies that require in vivo model systems, as 3D cultures can closely mimic a typical morphology and microarchitecture of organs, represents one of the key factors supporting the growth of the market. Besides this, there is a rise in the employment of 3D tissue-engineered models to diagnose cancer and other clinical disorders among the masses around the world. This, along with the growing demand for 3D cell culture to analyze the effects of a foreign drug over body tissues and organs, is offering a favorable market outlook. In addition, the rising demand for 3D cell culture, as it is a simple and inexpensive in vitro tumor-host environment compared to 2D techniques, is propelling the growth of the market. Moreover, the increasing usage of 3D models for performing research about respiratory diseases is offering lucrative growth opportunities to industry investors. Apart from this, there is an increase in the demand for airway and air-liquid interface organoids to develop and discover antiviral drugs and as experimental virology platforms and study the immune responses. This, coupled with the launch of new products and wide applications of 3D protocols in biological research, is strengthening the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global 3D cell culture market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product, application and end user.
The report has provided a detailed breakup and analysis of the 3D cell culture market based on the product. This includes scaffold-based platforms, scaffold-free platforms, microchips, bioreactors, and others. According to the report, scaffold-based platforms represented the largest segment.
A detailed breakup and analysis of the 3D cell culture market based on the application has also been provided in the report. This includes cancer research, stem cell research, drug discovery, regenerative medicine, and others. According to the report, cancer research accounted for the largest market share.
A detailed breakup and analysis of the 3D cell culture market based on the end user has also been provided in the report. This includes biotechnology and pharmaceutical companies, contract research laboratories, academic institutes, and others. According to the report, biotechnology and pharmaceutical companies accounted for the largest market share.
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America (the United States and Canada) was the largest market for 3D cell culture. Some of the factors driving the North America 3D cell culture market included the government funding for the development of advanced 3D cell culture models, high healthcare spending, the presence of a large number of universities and research organizations, etc.
The report has also provided a comprehensive analysis of the competitive landscape in the global 3D cell culture market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include 3D Biotek LLC, Advanced Biomatrix Inc., Avantor Inc., CN Bio Innovations Limited, Corning Incorporated, Emulate Inc., InSphero AG, Lonza Group AG, Merck KGaA, Promocell GmbH, Synthecon Inc, Thermo Fisher Scientific Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.